Krystal Biotech, Inc. (KRYS) Misses Q3 EPS by 8c

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $0.91, $0.08 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $82.94 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Western Digital (WDC) June 26 weekly options active, share price down 8.8% into Micron (MU) quarter results
• US DoE to Jumpstart Nuclear Supply Chain and Accelerate Deployment of Westinghouse AP1000 reactors